{
    "organizations": [],
    "uuid": "c21d7dad8c471a10cc32ee91e026e41ce49b25c0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-therapix-biosciences-expects-to-te/brief-therapix-biosciences-expects-to-test-thx-110-in-early-study-in-q2-idUSFWN1PX1A1",
    "ord_in_thread": 0,
    "title": "BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 7, 2018 / 1:36 PM / in 14 minutes BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2 Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Therapix Biosciences Ltd: \n* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018 \n* THERAPIX BIOSCIENCES - COMPLETES PRE-IND COMMUNICATION WITH FDA ON THX-110 FOR TOURETTE SYNDROME: CLINICAL DEVELOPMENT TO PROCEED AS PROJECTED Source text for Eikon: Further company coverage:",
    "published": "2018-02-07T21:36:00.000+02:00",
    "crawled": "2018-02-07T15:54:37.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "bioscience",
        "expects",
        "test",
        "early",
        "study",
        "q2",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "therapix",
        "bioscience",
        "ltd",
        "therapix",
        "bioscience",
        "ltd",
        "expect",
        "evaluate",
        "phase",
        "iib",
        "clinical",
        "study",
        "q2",
        "therapix",
        "bioscience",
        "completes",
        "communication",
        "fda",
        "tourette",
        "syndrome",
        "clinical",
        "development",
        "proceed",
        "projected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}